Posts by Muana Minkoué
Two life sciences startups shortlisted for the 31st Prix Strategis
Testmate Health and Seprify are among the eight semi-finalists of this year’s Prix Strategis. Every year for almost 30 years, HEC Espace Entreprise has awarded the Prix Strategis to some of the most promising Swiss start-up with a prize of CHF 50’000. The Strategis Prize is a springboard for young companies with high…
Read MoreAbionic appoints Patrick Pestalozzi as new CEO to propel company into next growth phase
Abionic SA, a Swiss leader in nanofluidic point-of-care diagnostic solutions, announced the appointment of Patrick Pestalozzi as its new CEO, effective 1 April 2024. A former Management Consultant, Silicon Valley executive, and entrepreneur, Patrick brings to Abionic three decades of global experience. In particular, he previously acted as the Vice-President of Global Strategic…
Read MoreCSEM and ClexBio create a bioreactor to manufacture tissue-engineered cardiovascular implants
A new type of bioreactor that can grow human veins in the lab has been developed by CSEM and ClexBio, a Nordics-based startup specialised in regenerative medicine. Funded by the Research Council of Norway, their solution aims to improve the lives of millions of people suffering from severe chronic venous insufficiency (CVI) by…
Read MoreThe Biopôle Review – 2023 edition
Check out all the key figures from Biopôle’s community, inspiring interviews and more in their latest review. Biopôle, the life sciences campus based in Lausanne, brings together a strong community of industry and academia. It offers a world-class combination of infrastructure, added value services, living space and community engagement where partners can thrive…
Read MoreAtinary and Takeda collaborate to drive innovation in healthcare
Atinary Technologies, a Vaud based startup, announced a strategic collaboration with Takeda, Japanese largest pharmaceutical company. This partnership brings together the two company’s complementary expertise, paving the way for innovative AI solutions poised to transform pharmaceutical R&D and accelerate drug discovery. Through this collaboration, Takeda will leverage Atinary’s leading AI Self-Driving Labs technology,…
Read MoreInnovative materials to combat bacteria
A UNIGE team is developing new alloys with bactericidal properties to combat antibiotic-resistant germs. While crucial to biotechnology, bacteria can also cause severe disease, exacerbated by their increasing resistance to antibiotics. This duality between economic benefits and infectious risks underlines the importance of finding ways to control their development. A team at the…
Read MoreAlys Pharmaceuticals launches with $100 Million financing from Medicxi
Formed through the aggregation of six-asset centric Medicxi companies, including Aldena Therapeutics, Alys boasts a robust R&D pipeline of cutting-edge programmes and platforms targeting multiple dermatological indications. Co-founded by Medicxi and several world-leading dermatology and scientific experts, Alys is a Boston and Geneva-based cutting edge pure-play immuno-dermatology company. It combines the assets and…
Read MoreCHF 870 Million invested in Swiss medtech and biotech companies
In the midst of an unfavourable environment, the life sciences’ sector continues to attract investors in Switzerland according to the Swiss Venture Capital Report 2024. In 2023, the downturn on the global venture capital market reached Switzerland. Swiss startups received a total of CHF 2.6 Billion last year, 35% less than in 2022.…
Read MoreFirst-in-Human implantation for Novostia’s heart valve
The Vaud-based startup, located at the Biopôle, successfully implanted its TRIFLO valve in a human. Novostia, a pioneering medical technology company, proudly announces a significant milestone in its mission to revolutionize cardiovascular care. Last December, the company has successfully implanted its groundbreaking TRIFLO Heart Valve in a human patient for the first time.…
Read MoreDebiopharm Innovation Fund invests in MedaSystems
MedaSystems secures additional funding from Debiopharm Innovation Fund to accelerate global access to pre-approval treatment. Medasystems, a pioneer in software to provide access to pre-approval medicine, announced funding from Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling…
Read More